HER2 intratumoral heterogeneity predicts response to neoadjuvant therapy in HER2-positive breast cancer: impact and interplay with HER3 expression
Angela Santoro(Ospedale Santa Maria Goretti), Antonino Mulè(Università Cattolica del Sacro Cuore)
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
October 30, 2025
Cited by 0
Related Papers
Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With Lymphoma
|Journal of Clinical Oncology|2010|167
Beta-Catenin and Epithelial Tumors: A Study Based on 374 Oropharyngeal Cancers
|BioMed Research International|2014|27